Lineage Cell Therapeutics Inc (STU:BT3)

Q2 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €0.967 (+0.21%)

Transcript 10-Q8-K

Key Points

Positve

Lineage Cell Therapeutics Inc (LCTX) extended its cash runway into the third quarter of 2028, one quarter longer than previously guided, providing greater financial stability.
The company successfully raised approximately $4.6 million through an ATM offering on Russell Reconstitution Day without negatively impacting its stock price, demonstrating prudent capital management.
Lineage Cell Therapeutics Inc (LCTX) reported net income of $1.5 million for Q2 2026, a significant improvement from a net loss of $30.5 million in the same period last year, driven by non-cash gains.
The Alascope manufacturing platform has demonstrated the ability to rapidly generate new pipeline assets, with the Core 1 corneal program advancing to preclinical testing just nine months after starting wet lab work.
Lineage Cell Therapeutics Inc (LCTX) remains eligible for up to $615 million in development and commercial milestones from the Roche/Genentech collaboration, alongside a double-digit tiered royalty on worldwide sales.
The company's OPC1 program is pivoting to a chronic spinal cord injury patient population, which offers a more stable neurological baseline, easier enrollment, and a larger patient pool compared to subacute patients.
Lineage Cell Therapeutics Inc (LCTX) successfully completed its first GMP run for the Resonance hearing loss program and established a novel deafening model for functional testing, advancing the partnership with Demant.
The company's ILT1 diabetes program is progressing well, having successfully demonstrated a fully suspension-based process for undifferentiated pluripotent cells at a multi-liter scale, addressing a key manufacturing hurdle.
Management highlighted that the Operigen program has received continued support from Roche, including expansion of the GALET study to 17 sites and registration in the EMA IRIS database, signaling ongoing commitment.

Negative

Lineage Cell Therapeutics Inc (LCTX) reported a decrease in total revenue to $1.1 million for Q2 2026, down from $2.8 million in the prior year, primarily due to lower collaboration revenue recognized under the Roche agreement.
R&D expenses increased by $1.7 million to $4.8 million in Q2 2026, driven by investments in preclinical programs, which could pressure future cash flows if not offset by partnership revenues.
The company's reported net income was primarily due to a non-cash gain from the remeasurement of warrant liabilities, which is not indicative of operational profitability and could reverse if the share price rises.
The OPC1 dose study is progressing slowly, with only two patients dosed to date and a mandatory one-month DSMB break between the first four patients, limiting the pace of enrollment and data generation.
Management remains intentionally vague about the scale and details of its Alloscope 5D manufacturing process, which may frustrate investors seeking clarity on the ILT1 program's competitive positioning.
The Operigen program's advancement into a multi-center controlled trial remains uncertain, with no definitive timeline provided, and the company relies on 'tea leaves' such as the EMA IRIS registration as indirect signals of progress.
Lineage Cell Therapeutics Inc (LCTX) faces significant manufacturing challenges in scaling islet cells for diabetes, with a 250,000-fold gap between current technology and commercial-scale needs, which may not be easily overcome.
The company's reliance on partnerships, such as the Demant collaboration for Resonance, introduces dependency on external funding and expertise, which could limit control over program development timelines.
General and administrative expenses increased by $0.7 million to $5.2 million in Q2 2026, driven by personnel and stock-based compensation, indicating rising overhead costs that could impact efficiency.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LCTX.A - Lineage Cell Therapeutics Inc
Q2 2026 Lineage Cell Therapeutics Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Lineage Cell Therapeutics Second Quarter 2026 Conference Call. At this time, all participants are in listen-only mode. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to the copyright and is the property of Lineage and recordings. Reproductions or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded.

I would now like to introduce your host for today's call, Iwana H1, Head of Investor Relations at Lineage. Ms. H1, please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.